Elevated systemic chemokine CCL5 is a predictive biomarker for post SAH complications and clinical outcome after aneurysmal subarachnoid hemorrhage (aSAH)
EANS Academy. Muhammad S. 09/27/19; 275930; EP01081
Assoc. Prof. Sajjad Muhammad
Assoc. Prof. Sajjad Muhammad

Access to this content is reserved for EANS members and attendees of this event. Click here to become an EANS member and gain your access to the full content of the EANS Academy

Discussion Forum (0)
Rate & Comment (0)
Background: Aneurysmal subarachnoid hemorrhage (aSAH) has the poorest outcomes among all stroke subtypes. Accumulating evidence suggests a critical role of inflammation in aSAH and post-aSAH complications. Chemokines play an important role in inflammation via leukocyte chemotaxis. Chemokine C-C motif ligand 5 (CCL5) is a potent pro-inflammatory chemokine shown to be upregulated in preclinical SAH studies. However, detailed clinical investigations are still lacking.
Objective: The current study investigated the role of systemic CCL5/RANTES after aSAH. The secondary aim was to determine associations between different post-aSAH complications and clinical outcome with systemic CCL5 levels.
Methods: We prospectively recruited 80 aSAH and 24 control patients. Peripheral venous blood was collected in serum gel tubes and centrifuged to harvest the serum, which was immediately frozen at -80°C until analysis. Serum CCL5 levels were quantified using enzyme-linked immunoassays. Age, gender, post-aSAH complications, aneurysm treatment, and clinical outcome (modified Rankin scale [mRS] and Glasgow outcome scale[GOS]) were retrieved from patient records.
Results: Serum CCL5 levels were significantly elevated after aSAH on days 1 and 7 in comparison with control patients. Dichotomization of patients to good (mRS 0-2 or GOS 4-5) and poor (mRS 3-6 or GOS 1-3) clinical outcomes showed that serum CCL5 levels were significantly higher in patients with good clinical outcome at discharge. Interestingly, CCL5 levels were significantly lower on day 7 in aSAH patients with intracerebral bleeding, chronic hydrocephalus, and pneumonia. Serum CCL5 levels on day 7 showed a positive correlation with clinical outcome (mRS and GOS).
Conclusion: Serum CCL5 levels were elevated during early and delayed brain injury phases after aSAH. Serum CCL5 levels on day 7 were independently associated with clinical outcome (mRS) at discharge.
Code of conduct/disclaimer available in General Terms & Conditions
Anonymous User Privacy Preferences

Strictly Necessary Cookies (Always Active)

MULTILEARNING platforms and tools hereinafter referred as “MLG SOFTWARE” are provided to you as pure educational platforms/services requiring cookies to operate. In the case of the MLG SOFTWARE, cookies are essential for the Platform to function properly for the provision of education. If these cookies are disabled, a large subset of the functionality provided by the Platform will either be unavailable or cease to work as expected. The MLG SOFTWARE do not capture non-essential activities such as menu items and listings you click on or pages viewed.

Performance Cookies

Performance cookies are used to analyse how visitors use a website in order to provide a better user experience.

Google Analytics is used for user behavior tracking/reporting. Google Analytics works in parallel and independently from MLG’s features. Google Analytics relies on cookies and these cookies can be used by Google to track users across different platforms/services.

Save Settings